Scientist.com Marketplace Expands to Include a Broad Selection of Ready-to-Use Life Science Reagents and Lab Supplies
Scientist.com, the premier R&D marketplace for the biopharmaceutical industry, announced that its users can now buy off-the-shelf reagents, lab supplies and consumables through the platform. Scientist.com users can access almost 5,000 research suppliers and purchase more than 15 million research products and services with ease. An easy check out process, simple search functionality and a dedicated customer support team make purchasing on the platform quick, reliable and cost efficient.
“In both large and small research organizations, many obstacles hinder research progress, including lengthy legal negotiations, supplier onboarding delays and inefficient order tracking," stated Diana Ourthiague, PhD, CCO of Scientist.com. "Scientist.com has created a highly efficient and comprehensive sourcing solution that eliminates these bottlenecks and enables researchers to carry out more innovative experiments in less time and at reduced cost.”
Virtually any preclinical research product or service can be sourced through Scientist.com. The platform enables researchers to work directly with multiple suppliers to design the exact lab experiment, study or service that’s needed for all their drug discovery projects. Popular services include human tissue sample acquisition, biomarkers, antibody creation, protein sciences, in vitro assays, disease models, compound synthesis, DNA and RNA sciences and value, evidence and access (VEA). With this expansion, Scientist.com users can now directly purchase millions of off-the-shelf antibodies, compounds, proteins, ELISA kits and other assay kits, lab supplies and consumables.
"Scientist.com simplified the purchase of our lab supplies and research services, enabling our researchers to spend more time on science and less time on paperwork. They provided outstanding customer service and supported every research request from start to finish,” stated John Donello, CSO of Boost Neuroscience, Inc. “Our finance team particularly appreciated one consolidated bill and the ability to leverage pre-negotiated discounts. We highly recommend Scientist.com to any stealth or established biotech that wants to improve research efficiency."
About Scientist.com
Scientist.com's mission is to empower and connect scientists worldwide. The company's digital research platform combines a custom-built, cloud native technology stack with white-glove customer and scientific support to enable scientists to run more innovative experiments in less time and at lower cost. Scientist.com leverages internally developed machine learning models to provide actionable insights that improve operational efficiency and effective research management. Scientist.com connects the world's top pharmaceutical companies, biotechnology companies and the US National Institutes of Health (NIH) to the world's largest network of scientific suppliers.
Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn, Twitter, YouTube, Facebook and Instagram
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230424005004/en/
Contact information
Sean Preci
marketing@scientist.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AYA Bank Goes Live with SmartStream's Digital Payments Platform7.5.2024 10:00:00 EEST | Press release
SmartStream, the financial Transaction Lifecycle Management (TLM®) solutions provider, today announces the successful implementation of its TLM Reconciliations Premium Digital Payments Control solution at AYA Bank, Myanmar’s premier banking institution. This implementation marks a significant advancement for the bank’s digital transformation journey. The industry has seen a recent surge in transaction volumes and AYA Bank recognised the need for an innovative tool capable of efficiently processing the influx of payment transactions. SmartStream’s TLM Reconciliations Premium Digital Payments Control will streamline various tasks including reconciliations, settlement, fee computation, and dispute resolution. Leveraging AI capabilities, the solution will facilitate rapid system adoption and comprehensive management of the bank’s transaction lifecycles. In addition, it will introduce a real-time oversight layer, further enhancing transaction transparency and automating accounting processes
Manhattan Unified Supply Chain Powers Schneider Electric’s Global Distribution and Transportation Transformation7.5.2024 10:00:00 EEST | Press release
Manhattan Associates Inc. (NASDAQ: MANH) today announced that leading global energy management and industrial automation organisation, Schneider Electric has chosen Manhattan Active® Warehouse Management and Manhattan Active® Transportation Management to supercharge its global distribution and transportation network as part of an ongoing business-wide transformation strategy. Manhattan Active® Supply Chain (the combination of Manhattan Active WM and Manhattan Active TM) will be implemented in over 20 distribution centres and Schneider Electric plans to deploy Manhattan Active TM across a further 200+ operational sites. Unifying both warehouse and transportation through Manhattan Active Supply Chain will bring maximum inventory performance, operational efficiency, and workforce agility to the company. Stuart Michael Whiting, senior vice president, GSC Logistics and Planning at Schneider Electric commented: “After 12 successful years with a Manhattan WMS, we decided to update to Manhatta
QVC Signs Multi-Year Contract Extensions with SES in Germany and the UK7.5.2024 09:50:00 EEST | Press release
Home shoppers across Germany, Austria and Switzerland as well as the United Kingdom and the Republic of Ireland will continue to receive an immersive, high-quality in-home shopping experience as QVC Germany and QVC UK have extended their partnerships with SES in multi-year agreements. For QVC Germany, the extension secures capacity on SES’s prime neighbourhood at the 19.2 degrees East for QVC HD, QVC2 HD and QVC Style HD channels. For QVC UK, the extension secures capacity over SES’s 28.2/28.5 degrees East satellites for QVC HD, QVC Style HD, QVC Beauty and QVC Extra as well as ground services, including uplinking, encoding and monitoring. QVC is a world leader in video commerce (vCommerce), which includes video-driven shopping across linear TV, ecommerce sites, digital streaming and social platforms. Since the 1990s, QVC has been leveraging SES’s satellites to broadcast their vCommerce channels to audiences in markets around the world. "The long-standing partnership with SES gives us
Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in Four Additional Countries7.5.2024 08:00:00 EEST | Press release
Galderma today announced that it has received filing acceptances for nemolizumab for the treatment of patients with prurigo nodularis and for adolescents and adults with moderate-to-severe atopic dermatitis in Australia, Singapore, Switzerland, and the United Kingdom, whose regulatory authorities are members of the Access Consortium. An approval decision is expected from the consortium next year. Nemolizumab is a therapy specifically inhibiting IL-31 signaling to provide safe and rapid relief from the most burdensome symptom of both skin conditions: itch.1-7 The Access Consortium is a collaborative initiative comprised of regulatory authorities which work together to address shared challenges, sharing knowledge and promoting greater collaboration to make regulatory systems more efficient.8 These acceptances are in addition to those received from the U.S. Food and Drug Administration (FDA) and European Medicines Agency for nemolizumab for the treatment of prurigo nodularis and atopic de
IFF Reports First Quarter 2024 Results7.5.2024 00:27:00 EEST | Press release
IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2024. Management Commentary "We have started the year well, with good results across the majority of our business," said IFF CEO Erik Fyrwald. "In the first quarter, we delivered volume growth and productivity gains, which resulted in solid top-and-bottom-line results on a comparable basis. We are off to a good start, yet recognize that it is still early in the year and uncertainty remains. Based on our performance to date and our outlook for the balance of the year, we believe results will likely trend towards the higher-end of our previously announced guidance ranges. We also took important steps in our portfolio optimization strategy by reaching an agreement to sell our Pharma Solutions business and completing the previously announced divestiture of our Cosmetic Ingredients business. These actions, along with the rightsizing of our dividend earlier this year, represent significant steps toward our commi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom